{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462093478
| ImageFile=Lonafarnib.svg
| ImageSize=200px
| IUPACName=<small>4-(2-{4-[(11''R'')-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-''b'']pyridin-11-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide</small>
| OtherNames= Sarasar (US), SCH 66336
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = IOW153004F
| IUPHAR_ligand = 8024
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 130645
| InChI = 1/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1
| InChIKey = DHMTURDWPRKSOA-RUZDIDTEBQ
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 47097
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 298734
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DHMTURDWPRKSOA-RUZDIDTESA-N 
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=193275-84-2
| PubChem=148195
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04768
| SMILES = C=12CCC=3C=C(C=C(C3[C@H](C1N=CC(=C2)Br)C4CCN(CC4)C(=O)CC5CCN(CC5)C(N)=O)Br)Cl
            
}}
|Section2={{Chembox Properties
| Formula=C<sub>27</sub>H<sub>31</sub>Br<sub>2</sub>ClN<sub>4</sub>O<sub>2</sub>
| MolarMass=638.82164
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Lonafarnib''' is a [[farnesyltransferase inhibitor]] (FTI) that has been investigated in a human clinical trial as a treatment for [[progeria]], which is an extremely rare [[genetic disorder]] in which symptoms resembling aspects of [[Senescence|aging]] are manifested at a very early age.<ref name="pmid17667598">{{cite journal |author=Liu G |title=Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336) |journal=Anticancer Drugs |volume=18 |issue=8 |pages=923–31 |year=2007 |pmid=17667598 |doi=10.1097/CAD.0b013e3280c1416e |name-list-format=vanc|author2=Marrinan CH |author3=Taylor SA |display-authors=3 |last4=Black |first4=S |last5=Basso |first5=AD |last6=Kirschmeier |first6=P |last7=Robert Bishop |first7=W |last8=Liu |first8=M |last9=Long |first9=BJ|doi-broken-date=2017-01-16 }}</ref><ref>[https://www.progeriaresearch.org/the-fti-drug/ “The FTI Drug Lonafarnib”], Progeria Research Foundation.  Accessed October 3, 2017.</ref>

Lonafarnib is a synthetic [[tricyclic]] derivative of [[carboxamide]] with [[antineoplastic]] properties.<ref>{{cite web | url = http://www.cancer.gov/drugdictionary?cdrid=43503 | title = Lonafarnib | work = NCI Drug Dictionary | publisher = National Cancer Institute}}</ref> As such, it is used primarily for cancer treatment. For those with progeria, research has shown that the drug reduces the prevalence of stroke and [[transient ischemic attack]], and the prevalence and frequency of headaches while taking the medication.<ref>{{cite journal | doi = 10.1212/WNL.0b013e31829d85c0 | title = Neurologic features of Hutchinson–Gilford progeria syndrome after lonafarnib treatment | year = 2013 | last1 = Ullrich | first1 = N. J. | last2 = Kieran | first2 = M. W. | last3 = Miller | first3 = D. T. | last4 = Gordon | first4 = L. B. | last5 = Cho | first5 = Y.-J. | last6 = Silvera | first6 = V. M. | last7 = Giobbie-Hurder | first7 = A. | last8 = Neuberg | first8 = D. | last9 = Kleinman | first9 = M. E. | journal = Neurology | volume = 81 | issue = 5 | pages = 427–30 | pmid = 23897869 | pmc = 3776537  }}</ref> A phase II clinical trial was completed in 2012, which showed that a cocktail of drugs that included lonafarnib and two other drugs met clinical efficacy endpoints that improved the height and diminished the rigidity of the bones of progeria patients.{{cn|date=May 2014}}

== References ==
<references/>

== See also ==
* [[Laminopathy]]

== External links ==
* [http://www.npr.org/blogs/health/2012/09/25/161691083/experimental-drug-is-first-to-help-kids-with-premature-aging-disease? "Experimental Drug Is First To Help Kids With Premature-Aging Disease"], [[NPR]], September 24, 2012

[[Category:Piperidines]]
[[Category:Ureas]]
[[Category:Benzocycloheptapyridines]]
[[Category:Organobromides]]
[[Category:Chloroarenes]]
[[Category:Farnesyltransferase inhibitors]]